Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414453 · ClinicalTrials.gov registry record · Phase 4
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
A Phase 4 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT00414453: Clinical Trial Phase 4 study, sponsored by University of Rochester.
NCT00414453 is a Phase 4 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414453, a Phase 4 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS). If treatment with topical lidocaine is efficacious, it will have important implications for understanding this chronic pain syndrome, which is widely assumed to be caused by central nervous system pathology.
Primary Outcome
subject identifies daily pain rating during final week of each treatment period using a numeric rating scale
Interventions
- DRUG Lidocaine patch 5%
- DRUG Extended-release oxycodone
- DRUG Placebo extended-release oxycodone pills
- DRUG Placebo lidocaine patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Why NCT00414453 stopped before completion
NCT00414453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Lidocaine patch 5% is the first listed.
NCT00414453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00414453 about?
NCT00414453 is a clinical study titled "Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis". This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS). If treatment with topical lidocaine is efficacious, it will have important implications fo...
What is the current status of trial NCT00414453?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2007-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00414453?
The interventions under investigation include: Lidocaine patch 5% (DRUG), Extended-release oxycodone (DRUG), Placebo extended-release oxycodone pills (DRUG), Placebo lidocaine patches (DRUG).
Who is sponsoring clinical trial NCT00414453?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00414453's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia